NVE Corp. Rating Lowered to Hold at TheStreet (NVEC)

Share on StockTwits

TheStreet downgraded shares of NVE Corp. (NASDAQ:NVEC) from a buy rating to a hold rating in a research note released on Friday morning, AnalystRatings.Net reports.

“NVE Corporation (NVEC) has been downgraded by TheStreet Ratings from buy to hold. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity.,” the firm’s analyst wrote.

Shares of NVE Corp. (NASDAQ:NVEC) opened at 55.26 on Friday. NVE Corp. has a 52 week low of $46.33 and a 52 week high of $60.49. The stock has a 50-day moving average of $56.5 and a 200-day moving average of $55.61. The company has a market cap of $267.8 million and a price-to-earnings ratio of 23.00.

NVE Corp. (NASDAQ:NVEC) last announced its earnings results on Wednesday, January 22nd. The company reported $0.57 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.63 by $0.06. The company had revenue of $6.47 million for the quarter, compared to the consensus estimate of $7.04 million. NVE Corp.’s revenue was down .9% compared to the same quarter last year. Analysts expect that NVE Corp. will post $2.43 EPS for the current fiscal year.

NVE Corporation (NASDAQ:NVEC) develops and sells devices that use spintronics, a nanotechnology that relies on electron spin.

To view TheStreet’s full report, visit TheStreet’s official website.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Netanyahu Sends Warning to Civilians in Gaza
Netanyahu Sends Warning to Civilians in Gaza
SAGE Therapeutics’ Quiet Period Will End  on August 27th
SAGE Therapeutics’ Quiet Period Will End on August 27th
RBC Capital Receives Consensus Recommendation of “Buy” from Analysts
RBC Capital Receives Consensus Recommendation of “Buy” from Analysts
Lowe's Companies Receives Average Recommendation of “Buy” from Brokerages
Lowe's Companies Receives Average Recommendation of “Buy” from Brokerages
Seattle Genetics Given Consensus Rating of “Hold” by Brokerages
Seattle Genetics Given Consensus Rating of “Hold” by Brokerages
SPX Receives Average Recommendation of “Hold” from Analysts
SPX Receives Average Recommendation of “Hold” from Analysts


Leave a Reply

 
© 2006-2014 Mideast Time.